论文部分内容阅读
本文对10例复发及难治性急性白血病使用A-3V疗法进行临床观察,其中复发5例,首次缓解诱导不成功即难治5例;急性髓性白血病(AML)8例(M25例,M 1、M3、M5各1例)。AML全部、ALLI例均采用过阿糖胞苷、柔红霉素联合疗法。A-3V的用法为:鬼臼乙叉甙(VP16)100mg/m~2静脉点滴30分钟,每日1次,持续5天;阿糖胞苷(Ara-C)100mg/m~2静脉点滴,每日1次,持续7天;长春新碱((VCR)0.8mg/m~2,于第10天静脉注射;长春花碱(VBL)6mg/m~2,第12天静脉注射。结果,AML8例全部有效,其中复发4例中有3例获完全缓解(CR),1例获部分缓解(PR);难治4例中有2例获CR,2例获PR。AML的CR率为
In this article, 10 cases of relapsed and refractory acute leukemia were treated with A-3V therapy, including 5 cases of recurrence, 5 cases of refractory to first remission induction, and 8 cases of acute myeloid leukemia (AML) (M25 cases, M). 1, M3, M5 each case). All AML and ALLI cases were treated with cytarabine and daunorubicin. The use of A-3V is: Erythrosporian glycoside (VP16) 100mg/m~2 intravenous drip for 30 minutes once a day for 5 days; Ara-C 100mg/m~2 intravenous drip , Once a day for 7 days; Vincristine ((VCR) 0.8mg/m~2, intravenous injection on the 10th day; Vinblastine (VBL) 6mg/m~2, IV on the 12th day. 8 cases of AML were all effective, of which 4 cases had remission (CR) in 4 cases, partial remission (PR) in 1 case, CR in 2 cases, PR in 2 cases, PR in 2 cases, and CR rate in AML. for